Microbiome Resource Center
Microbiome Resource Center
February 14, 2020
1 min read

Rebiotix completes enrollment for phase 3 trial of C. diff microbiota therapy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Investigators have completed enrollment in a phase 3 trial set to investigate RBX2660, a therapy that uses the gut microbiota to treat Clostridioides difficile infection, according to a press release issued by Rebiotix, the manufacturer.

The company said this is the first microbiota-based formulation to reach phase 3 in the United States and Canada.

“Microbiota-based therapies have shown tremendous potential as an innovative, non-antibiotic therapy, starting with C. diff, Rebiotix founder and CEO Lee Jones said in the press release. The completion of enrollment of this trial is a critical next step in making microbiota-based products accessible to patients - we are excited about this important milestone and look forward to sharing results later this year.”

RBX2660 was developed using the company’s microbiota-based MRT drug platform. A previous phase 2 trial found the drug was effective for the prevention of recurrent CDI.

The company plans to present clinical data to the FDA in a biological license application and believes RBX2660 will be the first microbiota-based therapy to obtain regulatory approval in the U.S.

Disclosure: Jones is employed by Rebiotix.